Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system for intrauterine use. It releases a low dose of hormone locally within the uterus to provide reliable, long‑term reversible contraception and prevent pregnancy in women of reproductive age seeking a highly effective birth‑control method.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for global markets.

Jaydess, a levonorgestrel intrauterine system, is used within the hormonal contraceptive pathway to prevent unintended pregnancy.

Contraception: provides long‑term, reversible birth control for women of reproductive age, reducing the risk of unintended pregnancy for up to three years and often resulting in lighter menstrual bleeding. Post‑abortion contraception: offers immediate, reliable contraception after surgical or medical abortion. Post‑partum contraception: can be inserted after delivery to deliver prompt contraceptive protection during the postpartum period.

Jaydess may be associated with a range of adverse reactions.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping - Breast tenderness - Headache - Mood changes

Serious or Rare Side Effects: - Uterine perforation during insertion - Pelvic inflammatory infection - IUS expulsion or displacement - Ectopic pregnancy if contraception fails - Allergic reaction (rash, swelling, anaphylaxis) - Ovarian cyst formation

Before insertion and during use, certain precautions should be observed.

Pregnancy screening: confirm the patient is not pregnant before placement. Uterine assessment: evaluate cavity size and shape to ensure suitability. Infection risk: avoid insertion in the presence of active pelvic infection. Bleeding counseling: inform about possible changes in menstrual patterns. Follow‑up: schedule post‑insertion checks to confirm correct positioning. Store at room temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel IUS has limited systemic drug interactions, but some agents may affect contraceptive efficacy.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) - Rifampicin or other strong CYP450 inducers - Certain antiretroviral therapies that reduce hormone levels

Moderate Interactions (Monitor Closely): - Antibiotics such as griseofulvin (potentially reduced effectiveness) - Herbal supplements containing St. John’s wort - Hormonal therapies that may increase side‑effect risk - Medications that alter uterine environment (e.g., uterotonics)